Printer Friendly

BELMAC REPORTS PROGRESS ON BIOLID(TM) IN FRANCE

 BELMAC REPORTS PROGRESS ON BIOLID(TM) IN FRANCE
 TAMPA, Fla., March 18 /PRNewswire/ -- Belmac Corporation


(AMEX: BLM) reported today on the progress in the marketing of its macrolide antibiotic Biolid(TM) in France. The company reported that it has been conducting a pre-marketing campaign and is now detailing Biolid(TM) to physicians with approximately 85 exclusive medical sales reps which is 30 more than previously announced. In addition, another 70 non-exclusive reps will be detailing the product within a few weeks, bringing the total number of reps to 150. A recent survey of physicians in France conducted by TVF, a French medical data processing company, indicated that Biolid(TM) was considered the 15th most recognized prescription drug on the French market in terms of awareness. Jean-Francois Rossignol, Ph.D., chairman and CEO stated that, "It's remarkable to achieve such recognition after only a few months of sales force activity."
 Biolid(TM) is a new patented form of erythromycin that studies to date show as having significantly improved absorption which leads to lower dosage requirements, greater efficacy, and better tolerance. The company's management plans to obtain appropriate regulatory approvals and launch all presentations of the product including a once-a-day in the United States and throughout Europe over the next three to four years. Belmac filed an IND for Biolid(TM) with the United States FDA in December 1991 and is currently conducting phase III clinical studies in 14 different centers in the United States.
 Belmac Corporation is engaged in the development, manufacturing, and marketing of ethical pharmaceutical products, focusing primarily on products with very large market potential. The company is currently marketing pharmaceutical products in France and Spain and is developing three new anti-infectives: Biolid(TM), for common bacterial infections; Azaquinone for tuberculosis and AIDS-related MAC; and Phenantramine for malaria along with Alphanon(R), a new transdermal anti-hemorrhoidal product.
 -0- 3/18/92
 /CONTACT: Russell Ketchum, vice president of investor relations of Belmac Corporation, 813-286-4401 or 800-877-6533/
 (BLM) CO: Belmac Corporation ST: Florida IN: MTC SU:


AK-AW -- FL002 -- 9102 03/18/92 09:36 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 18, 1992
Words:344
Previous Article:THE HENLEY GROUP COMMENCES SECONDARY OFFERING
Next Article:IMC FERTILIZER REPORTS 'OUTLOOK STILL GOOD' DESPITE DISAPPOINTING PRICES OF KEY PRODUCTS
Topics:


Related Articles
BELMAC ANNOUNCES REVENUES FOR FIRST QUARTER
BELMAC MARKETS SECOND PRODUCT IN FRANCE; COMPANY ACQUIRES AMODEX(TM) FROM FISONS PLC
BELMAC ENTERS SPANISH MARKET WITH RIMAFAR, S.A.; PHARMACEUTICAL MANUFACTURING CAPABILITY VITAL LINK IN EUROPEAN DISTRIBUTION
BELMAC FILES IND WITH FDA FOR BIOLID(TM); PHASE III CLINICAL TRIAL TO BEGIN IN FEBRUARY 1992
BELMAC ANNOUNCES SECOND QUARTER RESULTS
BELMAC COMMENTS ON RECENT STOCK PRICE
BELMAC REPORTS THIRD QUARTER 1992 RESULTS; REVENUES TOP $5,000,000 FOR THE QUARTER
BELMAC ANNOUNCES RESULTS OF CLINICAL STUDIES
BELMAC REPORTS RESULTS FOR FISCAL YEAR ENDED JUNE 30, 1992
BELMAC SEES SHARPLY IMPROVING FIRST QUARTER OPERATING RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters